Skip to Content

FDA Approves Avastin

Avastin Approved for treatment for Metastatic Colorectal Cancer

Avastin (bevacizumab) is a recombinant humanized monoclonal IgG1 antibody which in combination with intravenous 5-fluorouracil-based chemotherapy, is indicated for first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum.

Posted: February 2004

Related Articles:

Avastin (bevacizumab) FDA Approval History